Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30070881 | 0.89 | CYP3A4 (0.35) | CYP3A4CYP2C19TP53ALDH1A1MAPT | |
| SCHEMBL30070883 | 0.89 | CYP3A4 (0.35) | CYP3A4CYP2C19TP53ALDH1A1MAPT | |
| SCHEMBL30070872 | 0.88 | CYP3A4 (0.33) | CYP3A4CYP2C19TP53ALDH1A1MAPT | |
| SCHEMBL26096510 | 0.87 | ALDH1A1 (0.30) | ALDH1A1MEN1KMT2ANPC1POLB | |
| SCHEMBL26099256 | 0.81 | — | — | |
| SCHEMBL30070864 | 0.81 | — | — | |
| SCHEMBL26466566 | 0.77 | — | — | |
| SCHEMBL26466005 | 0.76 | ALDH1A1 (0.30) | CYP3A4TP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL26467582 | 0.76 | — | — | |
| SCHEMBL26466565 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4087583-B1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20230140132-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4087583-A1 | ARGINASE INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2022-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140132-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, PRMT1 | CYP3A4 1543/4885CYP2C19 958/4885TP53 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.